Scholar Rock Holding Corporation Common Stock earnings per share and revenue
On Nov 14, 2025, SRRK reported earnings of -0.90 USD per share (EPS) for Q3 25, missing the estimate of -0.85 USD, resulting in a -5.19% surprise. Revenue reached --, compared to an expected 51.00 thousand, with a -100.00% difference. The market reacted with a +24.41% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.91 USD, with revenue projected to reach -- USD, implying an increase of 1.11% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Scholar Rock Holding Corporation Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Scholar Rock Holding Corporation Common Stock reported EPS of -$0.90, missing estimates by -5.19%, and revenue of $0.00, -100% below expectations.
How did the market react to Scholar Rock Holding Corporation Common Stock's Q3 2025 earnings?
The stock price moved up 24.41%, changed from $30.07 before the earnings release to $37.41 the day after.
When is Scholar Rock Holding Corporation Common Stock expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Scholar Rock Holding Corporation Common Stock's next earnings report?
Based on 16
analysts, Scholar Rock Holding Corporation Common Stock is expected to report EPS of -$0.91 and revenue of -- for Q4 2025.